Effects of the Pharmabiotic U-21 under Conditions of a Combined Neuroinflammatory Model of Parkinson's Disease in Rats.

Autor: Stavrovskaya AV; Research Center of Neurology, Moscow, Russia. alla_stav@mail.ru., Voronkov DN; Research Center of Neurology, Moscow, Russia., Marsova MV; Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia., Olshansky AS; Research Center of Neurology, Moscow, Russia., Gushchina AS; Research Center of Neurology, Moscow, Russia., Danilenko VN; Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia., Illarioshkin SN; Research Center of Neurology, Moscow, Russia.
Jazyk: angličtina
Zdroj: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2024 Jun; Vol. 177 (2), pp. 225-230. Date of Electronic Publication: 2024 Aug 02.
DOI: 10.1007/s10517-024-06161-5
Abstrakt: Data on the participation of microbiota in the development of Parkinson's disease allow us to discuss the ability of bacterial preparations to influence the processes leading to neurodegeneration. We studied the effect of oral administration of Limosilactobacillus fermentum U-21 lyophilisate on a model of Parkinson's disease in rats induced by combined intranigral injection of LPS and systemic administration of paraquat. The toxins significantly increased the number of missteps in the "narrowing beam walking" test, but a tendency to a decrease in this parameter was shown after treatment with U-21. It should be noted that U-21 did not reduce the neuronal death in the substantia nigra, but mitigated the inflammatory glial response, decreased the accumulation of phosphorylated α-synuclein and complement protein C3. Our study demonstrated the efficiency of the combined model of parkinsonism and reduction of proinflammatory changes under the influence of pharmabiotic without changes in the nigral neuronal death and motor deficits.
(© 2024. Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: